inositol has been researched along with Acute Onset Vascular Dementia in 9 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Biochemical abnormalities in Alzheimer's Disease (AD), vascular dementia (VaD) and other primary degenerative dementias have been investigated using MRS." | 2.42 | 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. ( Jones, RS; Waldman, AD, 2004) |
| "Furthermore, patients suffering from vascular dementia (VD) had remarkably enhanced TMA/tCr ratios, potentially due to ongoing degradation of myelin." | 1.32 | Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. ( Dierks, T; Frölich, L; Gorriz, C; Herminghaus, S; Lanfermann, H; Maurer, K; Pilatus, U; Wittsack, HJ; Zanella, FE, 2003) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, F | 1 |
| Li, MX | 1 |
| Wang, Y | 1 |
| Tang, W | 1 |
| Watanabe, T | 2 |
| Shiino, A | 2 |
| Akiguchi, I | 2 |
| Shirakashi, Y | 1 |
| Kotani, E | 1 |
| Yoshimura, M | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Waldman, AD | 2 |
| Rai, GS | 1 |
| Herminghaus, S | 1 |
| Frölich, L | 1 |
| Gorriz, C | 1 |
| Pilatus, U | 1 |
| Dierks, T | 1 |
| Wittsack, HJ | 1 |
| Lanfermann, H | 1 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Marszał, E | 1 |
| Jamroz, E | 1 |
| Paprocka, J | 1 |
| Kluczewska, E | 1 |
| Sokół, M | 1 |
| Jones, RS | 1 |
| Kantarci, K | 1 |
| Petersen, RC | 1 |
| Boeve, BF | 1 |
| Knopman, DS | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 1 |
| Weigand, SD | 1 |
| Edland, SD | 1 |
| Smith, GE | 1 |
| Ivnik, RJ | 1 |
| Ferman, TJ | 1 |
| Tangalos, EG | 1 |
| Jack, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
1 review available for inositol and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Dementia, Vascular; Glutamic Acid; | 2004 |
2 trials available for inositol and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Dementia, Vascular; Diagnosis, Differenti | 2008 |
The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Brain Ischemia; Dementia, Vascular; Female; | 2012 |
6 other studies available for inositol and Acute Onset Vascular Dementia
| Article | Year |
|---|---|
[Effect of moxibustion on inositol requiring enzyme 1 / X-box binding protein 1 pathway in hippocampal CA1 region of rats with vascular dementia].
Topics: Animals; bcl-2-Associated X Protein; CA1 Region, Hippocampal; Dementia, Vascular; Inositol; Male; Mo | 2023 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognition Disorders; Creatinine; Dementia, Vascular | 2003 |
Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Dementia, Vascular; Energy Metabolism; Female; Glutamic Aci | 2003 |
Leukoencephalopathy with macrocephaly and mild clinical course.
Topics: Abnormalities, Multiple; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creatinine; Dementi | 2004 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |